# Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation

> **NCT04489706** · NA · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** Arsenic trioxide for injection

## Key facts

- **NCT ID:** NCT04489706
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-28
- **Primary completion:** 2021-11
- **Final completion:** 2022-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489706, "Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04489706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*